The increasing prevalence of patients on anticoagulant and antiplatelet therapy presents significant considerations for dental practitioners, particularly concerning bleeding risks during invasive procedures. This article provides an updated, evidence-based guide for managing such patients, emphasizing a balance between minimizing bleeding complications and preventing thromboembolic events. Key areas discussed include pharmacological insights, preoperative assessments, procedural adaptations, local hemostatic techniques, and postoperative care. The guidance aligns with the latest clinical recommendations to ensure safe and effective dental care.

Anticoagulant and antiplatelet medications are essential in preventing thromboembolic disorders, including atrial fibrillation, venous thromboembolism, and ischemic heart disease [1]. Consequently, dental professionals increasingly encounter patients undergoing such therapies. The primary clinical challenge lies in balancing bleeding risks during dental procedures while maintaining systemic thromboembolic protection [2]. Current guidelines advocate against routine discontinuation of anticoagulants or antiplatelets due to the significant risk of thrombotic events [3].

Pharmacological Overview

* Anticoagulants

Anticoagulants inhibit various components of the coagulation cascade, reducing clot formation. The primary classes include:

Vitamin K Antagonists (VKAs): Warfarin remains widely used, requiring regular monitoring of the International Normalized Ratio (INR) to ensure therapeutic efficacy and safety [4].

Direct Oral Anticoagulants (DOACs): These include direct thrombin inhibitors (e.g., dabigatran) and factor Xa inhibitors (e.g., rivaroxaban, apixaban, edoxaban), offering predictable pharmacokinetics without routine coagulation monitoring [5].

* Antiplatelet Agents

Antiplatelets prevent platelet aggregation and arterial thrombosis:

Aspirin: Irreversibly inhibits cyclooxygenase-1 (COX-1), decreasing thromboxane A2 and reducing platelet aggregation [6].

P2Y12 Inhibitors: Clopidogrel, prasugrel, and ticagrelor block the P2Y12 component of the ADP receptor, further inhibiting platelet aggregation [7].

Patients with coronary stents may receive dual antiplatelet therapy (DAPT), combining aspirin with a P2Y12 inhibitor to prevent stent thrombosis [8].

Preoperative Assessment

* Medical History Evaluation

A thorough history should document:

Indication for therapy (e.g., atrial fibrillation, coronary stents) [9].

Medication details (specific agents, dosages, therapy duration) [10].

Bleeding history, particularly in dental procedures [11].

* Laboratory Investigations

INR Monitoring: For VKA users, ensuring an INR within the therapeutic range (typically 2.0–3.0) before invasive procedures [12].

Renal Function Tests: Required for DOAC users, as renal clearance affects drug metabolism [13].

* Risk Stratification

Dental procedures can be categorized based on bleeding risk:

Low-risk: Simple extractions (1–3 teeth), supragingival scaling, restorative work [14].

High-risk: Multiple extractions, periodontal surgery, vascular-rich procedures [15].

Procedural Management

* Continuation of Therapy

Current evidence suggests that most dental procedures can be performed without discontinuing anticoagulants or antiplatelets, as the bleeding risk is manageable with local hemostatic measures [16].

* Timing of Procedures

DOACs: Schedule dental procedures at the trough plasma level (12–24 hours after the last dose) to minimize bleeding [17].

VKAs: Ensure INR remains within therapeutic limits on the day of the procedure [18].

* Local Hemostasis

To control bleeding:

Mechanical: Pressure application with gauze, hemostatic agents (gelatin sponges, oxidized cellulose), sutures [19].

Chemical: Tranexamic acid mouthwash stabilizes clots [20].

Biological: Fibrin sealants and collagen sponges aid clot formation [21].

Postoperative Management

* Patient Instructions

Bleeding control: Apply firm pressure with gauze for 30–60 minutes [22].

Activity restriction: Avoid strenuous activities for 24–48 hours [23].

Medication adherence: Patients must continue their antithrombotic regimen unless instructed otherwise by their physician [24].

* Pain Management

First-line: Acetaminophen (paracetamol) is preferred due to its minimal effect on bleeding risk [25].

NSAIDs caution: If necessary, selective COX-2 inhibitors may be considered after physician consultation [26].

Special Considerations

* Patients on Dual or Multiple Antithrombotic Therapies

Patients on DAPT or combined anticoagulant-antiplatelet therapy face higher bleeding risks. A multidisciplinary consultation (e.g., with a cardiologist) is advisable for elective procedures [27]. If urgent dental care is needed, strict local hemostatic measures should be employed [28].

* Emergency Situations

For uncontrolled bleeding:

Apply firm pressure with a hemostatic agent [29].

Administer local anesthesia with a vasoconstrictor to constrict blood vessels [30].

If persistent, refer to an emergency department for systemic hemostatic agents or transfusions [31].

The management of dental patients on anticoagulant and antiplatelet therapy requires a comprehensive understanding of pharmacology, risk assessment, and procedural strategies. By following current guidelines and utilizing local hemostatic measures, dental professionals can safely perform procedures without unnecessary therapy interruptions, thereby minimizing both bleeding and thromboembolic risks.